stockrow
Friday 6 November 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
- Revenue
- −98.4%
- EPS
- +80.9%
- Free cash flow
- −5.22%
Quarter to September 2026, against a year earlier
0.52
0.02
+4.00%
Follow APRE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 19.45 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (1.88) | |
P/B ratio |
— | — | — | 0.45 | |
Price to Tangible BV |
— | — | — | 0.45 | |
EV/Sales |
— | — | — | (31.65) | |
EV/EBITDA |
— | — | — | 0.68 | |
EV/Operating CF |
— | — | — | 0.70 | |
EV/FCF |
— | — | — | 0.70 | |
Quick Ratio |
9.52 | 13.33 | 8.77 | 5.28 | |
Current Ratio |
9.67 | 13.55 | 8.92 | 5.63 | |
Net Debt/EBITDA |
7.32 | 10.24 | 13.57 | 5.53 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
0.77 | 0.91 | 0.84 | 1.21 | |
Capex/Depreciation |
0.00 | (2.66) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 30,569.70% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 49,624.24% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 3,303.03% | |
Graham Net Nets |
— | — | — | 2.17 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (232.94%) | |
Free Cash Flow Yield |
— | — | — | (232.27%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.06) | (0.19) | (0.45) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.06) | (0.19) | (0.45) | |
Cash per Share |
0.71 | 0.77 | 3.16 | 2.23 | |
Shareholders Equity per Share |
0.64 | 0.72 | 2.83 | 1.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.64 | 0.72 | 2.83 | 1.90 | |
Free Cash Flow |
(3.73) | (3.29) | (2.76) | (2.96) | |
Working Capital |
34.46 | 38.82 | 41.95 | 12.80 | |
Capital Expenditures |
0.00 | (0.02) | — | — | |
Net Current Asset Value |
33.73 | 38.09 | 41.22 | 12.07 | |
EV/EBIT |
— | — | — | 0.68 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
0.95 | 1.07 | 2.11 | 1.03 | |
Average Assets |
26.57 | 29.80 | 33.92 | 19.96 | |
Average Common Equity |
22.51 | 25.94 | 28.57 | 15.87 |
Columns are period end dates · fundamentals updated 6 Nov 2026